FDA行业指南:第七类兽药主文件(用于研发和风险评估)

VIP免费
薛定谔的龙猫 2025-11-12 12 3.03MB 15 页 100质量币
侵权投诉
#260
󶈭󳔄󶍼󳡾󶩰󳔼󴲈󳗷󾘉󵰩󳖏󵼕󳫒󳮍
󷿏󷵪󷋅󳘱󾘊
󶽍󳔛󴨈󳩘
󶩊󴽉󴨈󳩘
󴸭󴨈󴋽󴲈󳗷󳗆󳙝󴚂󵍃󴠐󷃂󳕌󵰩󱜃
󷋸󳸩󱜋󶝕󷞧󳡭󴦦󱜌󷜛󵻦󳔮󴫑󳚜󵶅󴳦󴸠󳥎󴫑󳖥󴋺󴸭󶩊󴽉󴨈󳩘󵶅󴠐󷃂󱜃󵰶󴉑󴠐󷃂󷋸󴫑󳖥
󶣴 https://www.regulations.gov 󱜃󳕧󷹣󴠐󷃂󷋸󴋅󶣴󷿠󳯂󶩰󳯂󵷒󵹤󶊢󵬇󴍁󴽤󴽉󶊢󵬇󴀅
󾘉HFA-305󾘊󾘍󳸱󳹁󾘛󸅭󷣍󳡱󴓟󶙘󳡌󶗵󴌕󴔃󷐺󴔍󴌕󷓰 5630 󳫸 1061 󴊥󾘍󷞯󶘗 20852󱜃
󴥁󴸊󴠐󷃂󳹈󴖕󵏩󴴏󴽤󴽉󶘗󳫸 FDA-2024-D-5376󱜃
󴂃󷸁󶪸󳫗󴸊󳡴󴸭󴲈󳗷󵶅󴷵󴀛󳛢󴝰󾘍󷋸󶝕󶏼󶚏󳷾󷿠󳯂󶩰󳯂󵷒󵹤󶊢󵬇󴍁󳡾󶩰󳔮󴛄󵶅󵬴󴝪󳩛
󳡌󵭠󾘍󳸱󳹁󾘛󸅭󷣍󳡱󴓟󶙘󳡌󶗵󴌕󴔃󴲰󳹧󷛫󳗁󴖀󳸻 7500 󳫸󾘍󷞯󶘗 20855󾘍󵰶󷋞󾘛240-402-
0611󾘍󵰶󴉑󷞯󳗷󾘛lynne.boxer@fda.hhs.gov󱜃
󴂃󷸁󶪸󳫗󴸭󶩊󴽉󴨈󳩘󴲈󳗷󵶅󷾞󴀗󳥰󴸭󾘍󷋸󳬒󷿠󳯂󶩰󳯂󵷒󵹤󶊢󵬇󴍁󳡾󶩰󳔮󴛄󴱀󶉗󳔏󵏖󷃅
󴀅󾘉HFV-6󾘊󴫑󳣻󵰴󷋸󾘍󳸱󳹁󳔻󾘛󸅭󷣍󳡱󴓟󶙘󳡌󶗵󴌕󴔃󴲰󳹧󷛫󳗁󴖀󳸻 7500 󳫸󾘍󷞯󶘗
20855󱜃󳕠󳫰󳸩󳖓󶝕󶙒󳔋󴻦󷴆󾘍󶙒󳹁󳔻󾘛https://www.fda.gov/animal-veterinary󱜂https://
www.fda.gov/regulatory-information/search-fdaguidance-documents 󴤗 http://www.
regulations.gov󱜃
󶚏󳷾󳩬󵰠󳔏󳡭󳘘󴸎󳦢󷟩
󷿠󳯂󶩰󳯂󵷒󵹤󶊢󵬇󴍁
󳡾󶩰󳔮󴛄
2025 󴕵 1 󴸉
Contains Nonbinding Recommendations
Draft 󰜕Not for Implementation
󵷯󴙖
󴤒. 󶊁󳗌........................................................................................................................................... 1
II. 󴸰󷋮 .......................................................................................................................................... 2
A. 󳔄󶍼󳡾󶩰󳔼󴲈󳗷 ................................................................................................................. 2
B. 󵼕󳫒󾘉R&D󾘊 .................................................................................................................... 3
C. 󷿏󷵪󴊢󴻦 ............................................................................................................................ 3
3󱜃󶈭󳔄󶍼󳡾󶩰󳔼󴲈󳗷 .................................................................................................................... 3
A. 󳙖󴳷󷜃󵰩 VII 󳺌󶵛󴧠󴸻󴥀 ................................................................................................. 3
B. 󳛞󴋇󴜨.................................................................................................................................. 5
C. 󵰩󴤸󷐺󵰩 ............................................................................................................................. 5
D. 󳡴󳖏󳸩 VII 󳺌󶵛󴧠󳤷󷜡󷊿󴲾󳢆󴋺󳖨󳯂󷛜󶽍󳤇󶗅󵶅󶜄󶵒󳷡󶐡 ......................................... 5
E. 󶈭󳔄󶍼󸆍󷋂󳿱󴴏󵶅󳢆󴊺 .................................................................................................... 5
F. 󳡴󳖏󳙖󴳷󳔻󵼕󳫒󳮍󷿏󷵪󴊢󴻦󷊿󶇌 VII 󳺌󶵛󴧠󴀛󷚺󴽇󴺷󵶅󶀻󳚌 .................................. 10
IV. 󵼕󶅷󴽤󴽉 ............................................................................................................................... 11
A. 󳗁󳕉󴴰󵼕󶅷󴽤󴽉󾘠 ........................................................................................................... 11
B. 󳙖󴳷󴘁󳬰󵼕󶅷󴽤󴽉 ........................................................................................................... 11
C. 󵰩󴤸󷐺󵰩 ........................................................................................................................... 12
D. 󴗻󶇌󷌄󴻦󴽤󴽉󵶅󶀻󳚌 ....................................................................................................... 12
i
Contains Nonbinding Recommendations
Draft 󰜕Not for Implementation
󶈭󳔄󶍼󳡾󶩰󳔼󴲈󳗷󾘉󵰩󳖏󵼕󳫒󳮍󷿏󷵪󷋅󳘱󾘊
󶽍󳔛󴨈󳩘󶩊󴽉
󴸭󴨈󳩘󶩊󴽉󴊛󶅀󳬏󾘍󴌇󳗤󶽩󶚏󳷾󷿠󳯂󶩰󳯂󵷒󵹤󶊢󵬇󴍁󾘉FDA 󴤗󴸭󴍁󾘊󳸩󷋦󳔼󷾙󳔋󵶅
󴙔󳥎󷃃󵞺󱜃󴸭󴨈󳩘󳔎󳔻󳗼󳙖󳖻󵽯󶇌󳗼󳙖󴹄󳤪󾘍󴋺 FDA 󴤗󳡭󳘘󳕠󳔎󳡸󴸊󶖧󴹠󳦜󱜃󴂃󴺝
󴞩󵶅󴸀󳗤󴲺󵏖󶈧󳬉󷜃󵰩󵶅󵏖󴚌󵏖󷃅󷂂󵍃󾘍󴞩󳫰󳗦󷣈󵰩󷋦󴲺󵏖󱜃󴂃󷸁󷊩󷊻󴸀󳗤󴲺󵏖󾘍󷋸
󶝕󶏼󴸭󴨈󳩘󴼈󷾙󷽶󳔋󳤘󳣻󵶅󷐠󷐤󷋦󴨈󳩘󵶅 FDA 󴓦󳙝󳖻󳭙󱜃
I. 󶊁󳗌
󴸭󶽍󳔛󴨈󳩘󶩊󴽉󾘉GFI󾘊󴫑󳚜󳖇󳡴󳖏󳚀󵰩󶈭󳔄󶍼󳡾󶩰󳔼󴲈󳗷󾘉󶈭󳔄󶍼 VMF󾘊󷛜󶽍󵼕
󶅷󴘁󳫒󳮍󷿏󷵪󷋅󳘱󵶅󳛢󴝰󱜃1 󴸭󴨈󳩘󷛙󷋵󴴏󳖇󴘁󳫒󶜆󾘉󰜝󴞩󰜞󾘊󳸩󳙖󶃎󴟆󳢶󳔌󴖕󴘁
󳬰󶈭󳔄󶍼 VMF󱜃2 󴸭󴨈󳩘󵶅󶨄󳷵󳗆󷵑󳖏󶈭󳔄󶍼 VMF 󳸩󵼕󶅷󴘁󳫒󳮍󷿏󷵪󷋅󳘱󷋸󵍃󴲺
󷹣󵶅󳚀󵰩󱜃󴸭󴲈󳗷󴸫󵒊󳫋󶈭󳔄󶍼 VMF 󵶅󳡷󳗗󵙝󳸩󵰩󷜕󱜃
󴸭󴨈󳩘󶩊󴽉󳔮󴥁󷛱󵶅 VII 󳺌󳡾󶩰󳔼󴲈󳗷󵶅󳚀󵰩󷜃󵰩󳖏󳔏󳦩󵥪󶗇󶟟󱜂󶗅󶗈󳗦󳫋󳻻󳖏󶗇
󶟟󳮍󶗅󶗈󵶅󳖨󳯂󾘉ACTPs󾘊󱜂󳻻󳷡󵲘󵏖󳮍󳦩󵥪󷝘󳘡󴜨󳻻󳷡󶗅󴸊󴠐󴰺󳫙󾘉IGAs󾘊󵷹󳡴
󵶅󵼕󳫒󳛢󴝰󾘍󳗦󳫋󴋺 ACTPs 󳮍󳦩󵥪 IGA 󵶅󷿏󷵪󴊢󴻦󱜃󴋺󳖏󷛚󳖜󴲱󳺌󳖨󳯂󳮍󴛬󷜠󳫒
󴍖󵶅󴦁󴸰󾘍󳫰󶟾󴉙󳸩󵒊󳫋󳔎󳬍󶍼󳺌󵶅󵧭󵥺󵷒󶊢󶜄󷣐󾘍󷸁󷂂󵋕󳘡󶗠󳖨󳯂󴷵󴳪󳸱󳔏 CVM
󷛜󶽍󳖓󳦩󱜃CVM 󷊥󳔻󵛁󳦲󷛚󶃎󳖓󳦩󴚉󷣎󷂂󱜃󴂃󴸭󴨈󳩘󴥁󷛱󾘍󴘁󳫒󳖻󳭙󳫰󳗦󴘁󷊿 VII
󳺌󳡾󶩰󳔼󴲈󳗷󴹦󵒶󵷗󳔏 CVM 󵶅󷛚󳖜󳖓󳦩󱜃
󴸭 GFI 󵒊󳫋󳔥󶃎󴟆󴙣󾘍󳸩󷛚󳔥󶃎󴟆󴙣󳔌󾘍󴞩󴖕󴘁󳬰󶈭󳔄󶍼 VMF 󶜍󷹟󷌄󴻦󴲈󳗷󾘛
󸂗󳡉󾘍󴂃󴺝󴞩󵶅󳖨󳯂󴍟󳖏󵷹󳡴󶨄󵱵󾘍󴞩󴖕󴙔󴘁󷊿󴕷󶗵󴨂󳔁󳔫󳬉󷜃󵶅 VII 󳺌󶵛󴧠󷐨󴔂󷐧󴤸󱜃
󳔋󷛱󶍼󳤬󾘍󴕷󵰩󳖏󴊛󳕊󳔮󵶅󵼕󶅷󳔏󴘁󳫒󱜃
󴸭󴨈󳩘󱜃󴌾󶊢󴋺󷋖󸆍󵰩󳖨󳯂󵶅󵷹󳡴󷂂󵍃󳬍󴼸󷜃󵰩󾘉21 CFR󾘊
511.1󾘊󳔮󷃅󴊛󾘍󶵛󴧠󳔼󴲈󳗷󾘉VMF󾘊󳔻󳔏 FDA 󳡲󳖬󳛢󴝰󴫑󳚜󳖇󳫧󳔁󶃎󷜕󴚅󱜃󴤒󳗭
1
3 For the purposes of this document, gene therapy products modify or manipulate the expression of a gene or alter the
biological properties of living cells by introducing a new or modified gene to treat a disease.
2 For this GFI, the term developer includes sponsors, researchers, or any other individuals interacting with CVM
through the Type VII VMF.
1 VMFs are described at https://www.fda.gov/animal-veterinary/development-approval-process/veterinary-master-
files. GFIs concerning other VMFs, i.e., Types I-VI, are not relevant to Type VII.
摘要:

260NQoNeNuNxSTiO0LNcSWIhHcSWgceNNOlBaNKu0W0TQlb0wNcOvegRMcNgIhHcSWva0u5PacNhttpswwwregulationsgov0NfbaToTvwcthchHtYHFA305W0WlQpWQK95630S1061208520bgaWGlfhchHSFDA2024D53760YSgQsgeNvfYOoTVToTvwctQoNvt3iSZQKtW0WlQpWQKeWfNW7500S20855u52404020611u5PNlynneboxerfdahhsgov0YSgIhHcSWeNvYRogTToTvwctQoNeVNlYHFV...

展开>> 收起<<
FDA行业指南:第七类兽药主文件(用于研发和风险评估).pdf

共15页,预览15页

还剩页未读, 继续阅读

声明:如果您的权利被侵害,请联系我们的进行举报。
作者:薛定谔的龙猫 分类:专业资料 价格:100质量币 属性:15 页 大小:3.03MB 格式:PDF 时间:2025-11-12
/ 15
客服
关注